臨床外科67巻7号

2012年07月発行

特集 分子標的薬の有害事象とその対策

分子標的薬の副作用のトピックス，展望

著者： 森隆弘¹² 石岡千加史³⁴

所属機関： ¹東北大学大学院医学系研究科 ²東北大学病院がんセンター ³東北大学加齢医学研究所臨床腫瘍学分野 ⁴東北大学病院腫瘍内科

ページ範囲：P.862 - P.868

文献概要

【ポイント】

◆分子標的薬の毒性（副作用）プロファイルは殺細胞性抗がん薬とは異なる．

◆副作用回避や費用対効果改善のためにもバイオマーカーによるテーラーメード医療が必要である．

参考文献

1）Levitzki A, Gazit A.：Tyrosine kinase inhibition：an approach to drug development. Science 267：1782-1788, 1995

2）Sleijfer S, Wiemer E, Verweij J：Drug Insight：gastrointestinal stromal tumors（GIST）--the solid tumor model for cancer-specific treatment. Nat Clin Pract Oncol 5：102-111, 2008

3）Frankel AE, Fleming DR, Powell BL, et al：DAB389IL2（ONTAK）fusion protein therapy of chronic lymphocytic leukaemia. Expert Opin. Biol Ther 3：179-186, 2003

4）Kantarjian H, O'Brien S, Cortes J, et al：Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia（CML-CP）after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin. Cancer Res 10：68-75, 2004

5）Wang WL, Conley A, Reynoso D, et al：Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 1：S15-24, 2011

6）Apperley JF, Gardembas M, Melo JV, et al：Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347：481-487, 2002

7）Corless CL, Barnett CM, Heinrich MC：Gastrointestinal stromal tumours：origin and molecular oncology. Nat Rev Cancer 11：865-878, 2011

8）Maemondo M, Inoue A, Kobayashi K, et al：Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362：2380-2388, 2010

9）Toyooka S, Kiura K, Mitsudomi T：EGFR Mutation and Response of Lung Cancer to Gefitinib. N Engl J Med 352：2136, 2005

10）Pao W. Miller VA, Politi KA：Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Medicine 2：225-235, 2005

11）Chabner BA：Early accelerated approval for highly targeted cancer drugs. N Engl J Med 364：1087-1089, 2011

12）Dumont FJ, Melino MR, Staruch MJ, et al：The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 144：1418-1424, 1990

13）Altomare DA, Testa JR：Perturbations of the AKT signaling pathway in human cancer. Oncogene 24：7455-7464, 2005

14）Boratynska M, Watorek E, Smolska D, et al：Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc 39：2736, 2007

15）Motzer RJ, Escudier B, Oudard S, et al：Efficacy of everolimus in advanced renal cell carcinoma：a double-blind, randomised, placebo-controlled phase Ⅲ trial. Lancet 372：449-456, 2009

16）Richardson PG, Mitsiades C, Hideshima T, et al：Proteasome inhibition in the treatment of cancer. Cell Cycle 4：290-296, 2005

17）Scott SD：Rituximab：a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract 6：195-197, 1998

18）Récher C, Coiffier B, Haioun C, et al：Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma（LNH03-2B）：an open-label randomised phase 3 trial. Lancet 378：1858-1867, 2011

19）Trappe R, Oertel S, Leblond V, et al：Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder（PTLD）：the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 13：196-206, 2012

20）Romond EH, Perez EA, Bryant J, et al：Trastuzumab plus adjuvant chemotherapy for operable HER 2-positive breastcancer. N Engl J Med 353：1673-1684, 2005

21）Suzan F, Ammor M, Ribrag V：Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 345：1000, 2001

22）Zhang B, Wang J, Xu W：Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma：necessity of antiviral prophylaxis. Onkologie 33：537-539, 2010

23）Sheridan C：EGFR inhibitors embrace KRAS. Nat Biotechnol 26：839-840, 2008

24）Jimeno A, Messersmith WA, Hirsch FR, et al：KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer：practical application of patient selection. J Clin Oncol 27：1130-1136, 2009

25）Keefe DM, Bateman EH：Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol 9：98-109, 2011

26）Pomerantz RG, Mirvish ED, Geskin LJ：Cutaneous reactions to epidermal growth factor receptor inhibitors. J Drugs Dermatol 9：1229-1234, 2010

27）Lacouture ME, Maitland ML, Seqaert S, et al：A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18：509-522, 2010

28）Bhargava P：VEGF kinase inhibitors：how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol 297：R1-5, 2009

29）Bhargava P：VEGF kinase inhibitors：how do they cause hypertension? Am J Physiol Regul Integr Comp Physiol 297：R1-R5, 2009

30）Raschi E, Vasina V, Ursino MG, et al：Anticancer drugs and cardiotoxicity：insights and perspectives in the era of targeted therapy. Pharmacol Ther 125：196-218, 2010

31）Eschenhagen T, Force T, Ewer MS, et al：Cardiovascular side effects of cancer therapies：a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 13：1-10, 2011

32）Hartmann JT, Haap M, Kopp HG, et al：Tyrosine kinase inhibitors―a review on pharmacology, metabolism and side effects. Curr Drug Metab 10：470-481, 2009

33）Di Lorenzo G, Porta C, Bellmunt J, et al：Toxicities of targeted therapy and their management in kidney cancer. Eur Urol 59：526-540, 2011

34）Brown RL：Tyrosine kinase inhibitor-induced hypothyroidism：incidence, etiology, and management. Target Oncol 6：217-226, 2011

35）Peerzada MM, Spiro TP, Daw HA：Pulmonary toxicities of tyrosine kinase inhibitors. Clin Adv Hematol Oncol 9：824-836, 2011

36）Ando M, Okamoto I, Yamamoto N, et al：Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24：2549-2556, 2006

37）ノバルティス　ファーマ：アフィニトール錠5mg 添付文書．第3版．2011年12月改定

38）Soria JC, Blay JY, Spano JP, et al：Added value of molecular targeted agents in oncology. Ann Oncol 22：1703-1716, 2011

39）Mullard A：Next-generation proteasome blockers promise safer cancer therapy. Nat Med 18：7, 2012

40）O'Connor OA, Stewart AK, Vallone M, et al：. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib（PR-171）in patients with hematologic malignancies. Clin Cancer Res 15：7085-7091, 2009

41）Ando Y, Saka H, Ando M, et al：Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity：a pharmacogenetic analysis. Cancer Res 60：6921-6926, 2000

42）Yamane-Ohnuki N, Satoh M：Production of therapeutic antibodies with controlled fucosylation. MAbs 1：230-236, 2009